Tacrolimus and mycophenolate mofetil regimens in transplantation

Benefits and pitfalls

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Immunosuppression, although necessary to enable the graft to escape the consequences of immune surveillance, carries some risks for the patient. There is an associated increase in neoplasms, opportunistic infections and end-organ toxicity. In addition, even with excellent patient compliance, rejection (acute and chronic) remains a major limitation that contributes to the loss or decrease in the function of the allograft. New drugs have been added to the armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue grafts from cyclosporin-resistant rejection. With the availability of these immunosuppressive agents, it has become increasingly difficult to choose the appropriate combination of immunosuppressants with a beneficial effect for the patient and for the allograft. We describe 2 new immunosuppressive agents and some of their different uses in solid organ transplantation.

Original languageEnglish
Pages (from-to)395-407
Number of pages13
JournalBioDrugs
Volume11
Issue number6
DOIs
StatePublished - Jun 30 1999

Fingerprint

Mycophenolic Acid
Tacrolimus
Immunosuppressive Agents
Transplantation
Allografts
Transplants
Opportunistic Infections
Organ Transplantation
Patient Compliance
Immunosuppression
Cyclosporine
Pharmaceutical Preparations
Rejection (Psychology)
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Immunology and Allergy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Tacrolimus and mycophenolate mofetil regimens in transplantation : Benefits and pitfalls. / Ciancio, Gaetano; Burke, George W; Roth, David; Miller, Joshua.

In: BioDrugs, Vol. 11, No. 6, 30.06.1999, p. 395-407.

Research output: Contribution to journalArticle

@article{f507e1a159b24797b78173ad747f7552,
title = "Tacrolimus and mycophenolate mofetil regimens in transplantation: Benefits and pitfalls",
abstract = "Immunosuppression, although necessary to enable the graft to escape the consequences of immune surveillance, carries some risks for the patient. There is an associated increase in neoplasms, opportunistic infections and end-organ toxicity. In addition, even with excellent patient compliance, rejection (acute and chronic) remains a major limitation that contributes to the loss or decrease in the function of the allograft. New drugs have been added to the armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue grafts from cyclosporin-resistant rejection. With the availability of these immunosuppressive agents, it has become increasingly difficult to choose the appropriate combination of immunosuppressants with a beneficial effect for the patient and for the allograft. We describe 2 new immunosuppressive agents and some of their different uses in solid organ transplantation.",
author = "Gaetano Ciancio and Burke, {George W} and David Roth and Joshua Miller",
year = "1999",
month = "6",
day = "30",
doi = "10.2165/00063030-199911060-00004",
language = "English",
volume = "11",
pages = "395--407",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Tacrolimus and mycophenolate mofetil regimens in transplantation

T2 - Benefits and pitfalls

AU - Ciancio, Gaetano

AU - Burke, George W

AU - Roth, David

AU - Miller, Joshua

PY - 1999/6/30

Y1 - 1999/6/30

N2 - Immunosuppression, although necessary to enable the graft to escape the consequences of immune surveillance, carries some risks for the patient. There is an associated increase in neoplasms, opportunistic infections and end-organ toxicity. In addition, even with excellent patient compliance, rejection (acute and chronic) remains a major limitation that contributes to the loss or decrease in the function of the allograft. New drugs have been added to the armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue grafts from cyclosporin-resistant rejection. With the availability of these immunosuppressive agents, it has become increasingly difficult to choose the appropriate combination of immunosuppressants with a beneficial effect for the patient and for the allograft. We describe 2 new immunosuppressive agents and some of their different uses in solid organ transplantation.

AB - Immunosuppression, although necessary to enable the graft to escape the consequences of immune surveillance, carries some risks for the patient. There is an associated increase in neoplasms, opportunistic infections and end-organ toxicity. In addition, even with excellent patient compliance, rejection (acute and chronic) remains a major limitation that contributes to the loss or decrease in the function of the allograft. New drugs have been added to the armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue grafts from cyclosporin-resistant rejection. With the availability of these immunosuppressive agents, it has become increasingly difficult to choose the appropriate combination of immunosuppressants with a beneficial effect for the patient and for the allograft. We describe 2 new immunosuppressive agents and some of their different uses in solid organ transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0032981286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032981286&partnerID=8YFLogxK

U2 - 10.2165/00063030-199911060-00004

DO - 10.2165/00063030-199911060-00004

M3 - Article

VL - 11

SP - 395

EP - 407

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 6

ER -